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ABSTRACT 
Urinary bladder is a hollow, collapsible, smooth muscular organ shaped like a balloon, which is a part of the urinary system. The 
walls of urinary bladder consists of four layers namely mucosa, submucosa, muscularis and the serosa. The function of urinary 
bladder is to relax and store urine during filling and to contract forcefully in order to empty the bladder during micturition. The 
nervous system monitors and controls almost every movement of urinary bladder through a series of positive and negative feedback 
loops. Diabetes mellitus (DM) is a rampant epidemic worldwide. DM affects more than 285 million people worldwide in 2010 and it 
estimated that it would affect 439 million by the year 2030. This review focuses on pathophysiological mechanisms responsible for 
urologic complications of diabetes and emphasizing on recent developments in our understanding of this condition. We also tried to 
shed some light on molecular biology which takes place during diabetes mellitus urinary bladder complications.  
Keywords: Urinary bladder detrusor muscle, Role of nervous system, Excitation-contraction coupling, Diabetes, Diabetic 
neuropathy, Diabetic retinopathy, Diabetic nephropathy. 
 
INTRODUCTION 
evelopment and Structure of Urinary Bladder 
In the fetus, development of the urinary 
bladder starts around the 8th week when it 
differentiates into smooth muscle and 
transitional epithelium. Urinary bladder is developed 
from the intermediate mesoderm of the fetus. The fetal 
bladder starts filling with urine by about 10 weeks. The 
bladder fills and empties approximately every 60minutes. 
The fetal urinary production is approximately 15mL/hr at 
30 weeks, which reaches 30 mL/hr towards the end of 
pregnancy. It empties every 30-60 min. The size of the 
bladder varies over a large range between species. For 
mouse and rat, the bladder capacity is 0.15 mL and 1 mL 
respectively.1 
Urinary bladder is a hollow, collapsible, smooth muscular 
organ shaped like a balloon, which is a part of the urinary 
system. Initially, at birth in infants the bladder is relatively 
in higher position than in the adult. It is in the abdominal 
rather than pelvic, extending about two-thirds of the 
distance towards the umbilicus. It progressively lowers 
down and reaches to the adult position shortly after the 
puberty.2The dimension of urinary bladder varies 
according to the differing in the urine content and sex of 
the animal or human. In females, urinary bladder is 
smaller because the uterus occupies the space just 
superior to the urinary bladder.3A moderately full bladder 
is 12 cm long but it can become double the size if 
necessary. Although urine is produced daily, it can be 
stored in the bladder until its release is convenient. In 
males, urinary bladder is directly anterior to the rectum 
while in females, it is anterior to the vagina and inferior to 
the uterus. In females, urinary bladder is a continuation 
of the uterus.4 
Urinary bladder is made up of several parts namely - 
dome, body, fundus and the neck. The body and fundus 
of the urinary bladder is highly mobile and highly 
distensible and have the capacity to expand into 
abdomen according to the volume of urine. In contrast, 
bladder base is relatively indistensible.5 The folds of the 
peritoneum hold the urinary bladder in position. The apex 
of urinary bladder is superior to the pubis symphysis 
whereas the fundus is a triangular and postero-inferior. 
There is no special constriction in the neck of the 
bladder.2 In males, it is in direct continuity with the base 
of prostrate whereas in females it related to the pelvic 
fascia, which surrounds the upper urethra. In both sexes, 
the superior surface is covered by peritoneum but the 
posterior surface lacks peritoneum.3 
The urinary bladder empties into the urethra, which is a 
continuation of the neck, where the uterus enters the 
urinary bladder and urethra joins the bladder forming the 
trigone on the mucosa.2When empty, the bladder 
collapses into its pyramidal shape where its muscular 
walls are thick and contains rugae. However as bladder is 
filled with urine it becomes spherical and the muscular 
wall becomes thinner and rugae disappear as the volume 
further increases and bladder becomes pear shaped. Both 
openings of uterus have valves, which are made up of 
mucosa to prevent back flow from the bladder to the 
ureters. There are three openings in the floor of the 
urinary bladder. Two of the openings are from the ureters 
and form the base of the trigone. The third opening is at 
the apex of the trigone that opens into the urethra. A 
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band of the detrusor muscle encircles this opening to 
form the internal urethral sphincter.3 
Detrusor Muscles in Urinary Bladder 
In human detrusor, there are bundles of muscle cells of 
varying size, which are surrounded by connective tissue 
and they are rich in collagen. These bundles vary 
extensively in size. In the human detrusor, they are large, 
a few millimeters in diameter and are composed of 
several smaller sub-bundles. These bundles are not 
clearly arranged in distinct layers, but run in all directions. 
Cells with long dendritic processes can be found parallel 
to the smooth muscle fibers. These cells contain vimentin 
as an intermediate filament protein which is expressed by 
cells of mesenchymal origin and non-muscle myosin.6 
The individual muscle cells in the detrusor are typical 
smooth muscle cells. They are long, spindle-shaped cells 
with a central nucleus. When fully relaxed, the cells are 
several hundred microns long and the widest diameter is 
5–6 µm. The cytoplasm packs with the normal 
myofilaments and the membranes contains regularly 
spaced dense bands with membrane vesicles. There are 
also scattered dense bodies in the cytoplasm.7 
Urinary Bladder Wall 
The walls of urinary bladder consists of four layers namely 
mucosa, submucosa, muscularis and the serosa. The 
mucosa is the innermost layer, which has a structure 
similar to the uterus. This layer is very thick and smooth 
containing transitional epithelium.8Surrounding the 
mucosa, submucosa layer is present. The second layer in 
the walls is the submucosa that supports the mucous 
membrane. It is composed of connective tissue with 
elastic fibers. The next layer is the muscularis, which is 
composed of smooth muscle. The smooth muscle fibers 
are interwoven in all directions and collectively called 
detrusor muscle. Contraction of this muscle expels urine 
from the bladder.3 The serous layer is the outermost 
layer. It is found only on the superior surface of the 
bladder. It is actually a continuation of the peritoneum.2 
Functions of the Urinary Bladder 
The function of urinary bladder is to relax and store urine 
during filling and to contract forcefully in order to empty 
the bladder during micturition. The urinary bladder 
functions as a transient reservoir for urine and various 
solutes with the capacity to hold up to 700 -800 mL of 
urine which is brought from kidney through ureters.9 
Storage of urine occurs at a low pressure. During filling of 
the urinary bladder, the smooth muscle cells haveto relax, 
elongate and rearrange in the wall over a very large 
length interval.Disturbances of the storage function may 
result in lower urinary tract symptoms (LUTS) such as 
urgency, frequency and urge incontinence are the 
components of the overactive bladder syndrome. LUTS is 
marked with age in both males and females and is a 
major problem in the elderly population. The overactive 
bladder syndrome is due to involuntary contractions of 
the smooth muscle of the bladder during the storage 
phase.10  
Urine is expelled from the urinary bladder and ultimately 
from the body by a process known as micturition. This 
process is also known as voiding or urination. During 
micturition, force generation and shortening must be 
initiated comparatively fast and occurs over a larger 
length range.11 In adults, this process is under voluntary 
control. The contractile function of smooth muscle 
involves the functional interplay of multiple processes 
including neurotransmitter receptor activation, 
intracellular Ca2+ signalling and ion channel regulation of 
membrane excitability. Failure at the level of neural 
regulation or smooth muscle contractile function can lead 
to incomplete bladder emptying.12 When the volume of 
urine in the urinary bladder exceeds 200- 400 mL, 
pressure within the bladder increases considerably and 
the stretch receptors in its walls transmit nerve impulses 
into spinal cord via spino-bulbo-spinal pathway which 
passes through the relay centre in the brain. The impulses 
propagate through spinal cord segments S2 and S3 and 
trigger spinal reflex called ‘micturition reflex’. Effective 
urine voiding is achieved by the complex interaction 
between coordinated contraction of the urinary bladder 
detrusor smooth muscle and relaxation by central 
nervous system (CNS) and peripheral nervous system 
(PNS).13 
Innervations of Urinary Bladder 
The nervous system monitors and controls almost every 
organ system through a series of positive and negative 
feedback loops. The CNS includes the brain and spinal 
cord while PNS connects the CNS to other parts of the 
body and is composed of bundles of neurons. The urinary 
bladder serves two main functions: the storage of urine 
without leakage and the periodic release of urine. These 
functions are dependent on central as well as peripheral 
autonomic and somatic neural pathways.14 
Parasympathetic Nervous System 
The parasympathetic nervous system is responsible for 
major excitatory input to the bladder. This system 
regulates ‘‘rest and digest’’ functions which means this 
system controls basic bodily functions. Parasympathetic 
preganglionic axons originate from the column of the S2 
to S4 spinal cord terminates on postganglionic neurons in 
the bladder wall and in the pelvic plexus. Neurons of PNS 
emerge from the brainstem as part of the cranial nerves 
III, VII, IX and X nerve and also from the sacral region of 
the spinal cord via sacral nerves 2, 3 and 4.5The 
parasympathetic preganglionic axons release 
acetylcholine (ACh) which activates postsynaptic nicotinic 
receptors. Nicotinic transmission at ganglionic synapses 
can be regulated by various modulatory synaptic 
mechanisms that involve muscarinic, adrenergic, 
purinergic and enkephalinergic receptors. 
Parasympathetic postganglionic neurons in turn provide 
an excitatory input to the bladder smooth muscle. 
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Adenosine triphosphate (ATP) is a co-transmitter, which is 
released from parasympathetic postganglionic terminals 
and acts on purinergic receptors to induce a rapid 
contraction of the bladder. Due to the presence of ATP, 
antimuscarinic agents do not completely abolish evoked 
bladder contractions in humans.14 
Sympathetic Nervous System 
The sympathetic nervous system is a part of the 
autonomic system that are connected with the spinal 
roots from the second thoracic (T2) to the second lumbar 
(L2). Sympathetic nervous system is distributed 
throughout the body. The sympathetic nervous system 
controls ‘‘fight-or-flight’’ responses which means the 
system prepares the body for strenuous physical activity. 
Most of preganglionic axons are short and synapse with 
postganglionic neurons within ganglia found in the 
sympathetic ganglion chains. Sympathetic postganglionic 
terminals releases norepinephrine to elicit contractions of 
the bladder base and urethral smooth muscle and 
relaxation of the bladder body mediated mainly through 
α1 and β2 adrenoceptors.15 
Excitation Contraction Coupling (ECC) 
Excitation-Contraction Coupling (ECC) is a process 
whereby an action potential causes a myocyte to 
contract. Smooth muscle contraction is initiated by an 
increase in the intracellular Ca2+ concentration. In 
principle, Ca2+ can enter the cytoplasm through the cell 
membrane via Ca2+ channels or released from the 
sarcoplasmic reticulum (SR). The release of Ca2+ from the 
SR is an important step in activation of the detrusor 
muscle. The release of Ca2+ triggers by inositol 
trisphosphate (IP3) via IP3 receptors and by Ca2+ via 
ryanodine receptors. The Ca2+ activation of the contractile 
proteins is considered to occur via a phosphorylation 
pathway where Ca2+ binds to calmodulin and the Ca2+ 
/calmodulin complex activates the Myosin Light-Chain 
Kinase (MLCK) which catalyzes the phosphorylation of the 
20-kDa myosin regulatory light chains on serine at 
position 19. This MLCK uses ATP to add a phosphate 
group to a portion of the myosin head. Once the 
phosphate group is attached myosin head starts to bind 
with actin and after that contraction occurs. After 
contraction, Ca2+ moves slowly out of the muscle fibre, 
which delays contraction. The prolonged presence of Ca2+ 
in the cytosol provides a state of continued partial 
contraction. Contraction in smooth muscle fibre starts 
more slowly and lasts much longer than skeletal muscle 
fibre contraction. Another difference is that the smooth 
muscle can shorten and stretch more than other muscle 
type.4 
Role of Calcium in Smooth Muscle Contraction 
By increasing the intracellular Ca2+ concentration, smooth 
muscle contraction initiated. There is 10,000-fold 
difference in the Ca2+ concentration between the 
extracellular and intracellular medium of the cell. SR, 
mitochondria and plasma membrane are the sites in the 
smooth muscle from where calcium can be released or 
accumulated. Smooth muscle contraction is initiated by 
an increase in the intracellular Ca2+ concentration.5In the 
urinary bladder muscle, various neurotransmitters like 
acetylcholine are released from motor nerve endings. This 
acetylcholine binds to specific receptors to activate 
contraction in smooth muscle. Subsequent to this 
binding, the typical response of the cell is to increase 
phospholipase C (PLC) activity via coupling through a G 
protein. PLC produces two potent second messengers 
from the membrane lipid phosphatidylinositol 4,5-
bisphosphate diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). IP3 binds to specific receptors on the 
sarcoplasmic reticulum, which causes release of activator 
Ca2+.16,17 DAG along with Ca2+ activates PKC which 
phosphorylates specific target proteins. In most smooth 
muscles, PKC has contraction-promoting effects such as 
phosphorylation of Ca2+ channels that regulate cross-
bridge cycling. Activator Ca2+ binds to calmodulin, leading 
to activation of myosin light chain kinase. This kinase 
phosphorylates the light chain of myosin and in 
conjunction with actin, cross-bridge cycling occurs which 
start initiating shortening of the smooth muscle cell.18,11 
This Ca2+ can enter the cytoplasm through the cell 
membrane via Ca2+ channels or released from the 
sarcoplasmic reticulum (SR). The release of Ca2+ from the 
SR is an important step in activation of the detrusor 
muscle. The Ca2+ activation of the contractile proteins is 
considered to occur via a phosphorylation pathway where 
Ca2+ binds to calmodulin to form Ca2+ - calmodulin 
complex. This complex activates the MLCK which 
catalyzes the phosphorylation of the myosin regulatory 
light chains. The Ca2+ induced activation of MLCK and the 
MLCP activity are the main pathways for contraction and 
relaxation. Ca2+ concentration and myosin light-chain 
phosphorylation is variable in the muscle. The 
phosphorylated myosin interacts with the actin filaments 
to form cross- bridges. The cross- bridges between actin 
and myosin continue if the intracellular calcium is 
maintained but if there is some declination of Ca2+, the 
enzyme myosin phosphatase is activated.11As a result, 
appropriate contraction occurs in urinary bladder 
muscles. 
Relaxation of the Smooth Muscle of Urinary Bladder 
Smooth muscle relaxation occurs as either a result or 
removal of the contractile stimulus or by the direct action 
of a substance that stimulates inhibition of the contractile 
mechanism.18 The process of relaxation requires a 
decreased intracellular Ca2+concentration and increased 
MLC phosphatase activity. Decreases in the intracellular 
concentration of Ca2+ elicit smooth muscle cell relaxation. 
Ca2+uptake into the sarcoplasmic reticulum is dependent 
on the ATP hydrolysis. This sarcoplasmic reticular Ca, Mg-
ATPase when phosphorylated binds to  two Ca2+ions 
which are then translocated to the luminal side of the 
sarcoplasmic reticulum and released.19 
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Na+/Ca2+exchangers are also located on the plasma 
membrane and aid in decreasing intracellular Ca2+. During 
relaxation, receptor- and voltage-operated Ca2+channels 
in the plasma membrane close resulting in a reduced 
Ca2+entry into the cell. Mg2+ also necessary for the activity 
of the enzyme binds to the catalytic site of the ATPase to 
mediate the reaction. The plasma membrane also 
contains Ca,Mg-ATPases which provides an additional 
mechanism for reducing the concentration of activator 
Ca+2 in the cell. This enzyme differs from the sarcoplasmic 
reticular protein in that it has an auto inhibitory domain 
that can be bound by calmodulin; causing stimulation of 
the plasma membrane Ca2+ pump.20 
Diabetes Mellitus 
Diabetes mellitus (DM) is a disease that was recognized in 
antiquity. The term “diabetes mellitus” was first used in 
the 18th century to distinguish the sweet taste of diabetic 
urine from other polyuric states in which the urine was 
tasteless. The first major breakthrough in the history of 
this disease occurred in 1921 when Banting and Best 
discovered insulin.21 Diabetes mellitus (DM) is a condition 
in which the pancreas no longer produces enough insulin 
or when cells stop responding to the insulin that is 
produced due to which glucose in the blood cannot be 
absorbed into the cells of the body this leads to 
hyperglycemia in the urine.22 
DM is a syndrome with metabolic, vascular, and 
neuropathic components that are all interrelated. The 
metabolic syndrome is characterised by alterations in 
carbohydrate, fat, and protein metabolism. The body's 
primary energy source is glucose which is obtained from 
the digestion of foods containing carbohydrates. Glucose 
from the digested food circulates in the blood as a ready 
energy source for any cells. Insulin is a chief hormone 
produced by cells in the pancreas. Insulin binds to a 
receptor site on the outside of cell and acts like a key to 
open a doorway into the cell through which glucose can 
enter. Some of the glucose can be converted to 
concentrated energy sources like glycogen or fatty acids 
and saved for later use. When there is not enough insulin 
produced or when the doorway no longer recognizes the 
insulin key, glucose stays in the blood rather than 
entering the cells.23 Diabetes and urologic diseases are 
very common health problems that markedly increase in 
prevalence and incidence with advancing age. Diabetes is 
associated with an earlier onset and increased severity of 
urologic diseases that results in costly and debilitating 
urologic complications. Urologic complications, including 
bladder dysfunction, sexual and erectile dysfunction, as 
well as Urinary Tract Infections (UTIs), have a profound 
effect on the quality of life of men and women with 
diabetes.24 
Diabetes mellitus (DM) is a rampant epidemic worldwide. 
DM affects more than 285 million people worldwide in 
2010 and it estimated that it would affect 439 million by 
the year 2030.25Diabetes is fast gaining the status of a 
potential epidemic in India with more than 62 million 
diabetic individuals currently diagnosed with the 
disease.26 In 2000, India (31.7 million) topped the world 
with the highest number of people with diabetes mellitus 
followed by China (20.8 million) with the United States 
(17.7 million) in second and third place respectively.27 The 
prevalence of diabetes is predicted to double globally 
from 171 million in 2000 to 366 million in 2030 with a 
maximum increase in India. It is predicted that by 2030 
diabetes mellitus may afflict up to 79.4 million individuals 
in India, while China (42.3 million) and the United States 
(30.3 million) will also see significant increases in those 
affected by the disease.28 
Diabetes can be classified into two different forms – 
Type I diabetes mellitus also known as insulin- dependent 
diabetes (IDDM) or juvenile diabetes. 
Type II diabetes mellitus is known as non- insulin- 
dependent diabetes (NIDDM) or adult onset.29 
Type I Diabetes Mellitus (IDDM) 
This accounts for only 10-15% of all cases of diabetes. 
Result from a study of 27 countries showed that the 
incidence of type I diabetes is on the rise by around 3% 
per year.30 Type I diabetes can be subdivided into a) 
Autoimmune and b) Idiopathic form. The autoimmune 
form is by far the most common and results from a cell-
mediated autoimmune destruction of the pancreatic beta 
cells. Type I DM is a slowly progressive thyroid T cell – 
mediated autoimmune disease including thyroid disease, 
Addison’s disease and vitiligo. In Type I diabetes, the body 
produces little or no insulin. This diabetes found in 
younger peoples, less than 40 years old.31,32Under this 
condition, patient needs exogenous insulin to reverse 
catabolic condition, prevent ketosis and decreases 
hyperglucagonemia.29 If anybody has type I diabetes, they 
require regular insulin injections for the rest of life in 
order to keep your glucose levels normal. Insulin 
injections can be administered using injection pen. Most 
people need either 2-4 injections a day. An alternative to 
injecting insulin is insulin pump therapy. The intense 
insulin therapy with glargine which is biosynthetic insulin 
is used to give lower fasting blood glucose as compared 
with fever episodes of hypoglycaemia as compared with 
twice daily Neutral Protamine Hagedorn insulin (NPH) in 
patient with type I diabetes.33 A small proportion of 
patients with type I diabetes will fall into the idiopathic 
form.34 This form of diabetes is strongly inherited caused 
by decreased insulin secretion and lacks immunological 
evidence for autoimmunity. 
Type II Diabetes Mellitus (NIDDM) 
Type II DM is more complex condition than type I DM 
because there is a combination of resistance to the action 
of insulin in liver and muscle together with impaired 
pancreatic β- cell function which leads to insulin 
deficiency.35 Type II DM is principally a disease of middle – 
aged. In United Kingdom, it affects 10 % of the population 
over 65 and over 70 % of all cases of diabetes occur after 
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the age of 50 years.31The prevalence of type II DM 
increases with age but varies between different 
populations. The prevalence is higher in certain ethinic 
groups: South Asians and Afro-Caribbean’s have sixfold 
higher risk compared to white populations.36 Diabetes can 
not be cured but it can be kept in control to prevent 
health problems later in life. If anybody has type II 
diabetes, they have to lose weight, make changes in their 
diet and taking regular exercise. Sometime people with 
type II diabetes require tablets insulin injections.22 Eber 
Papyrus was the first person who listed the symptoms of 
disease. DM is one of the leading causes of morbidity and 
mortality in the world with long term effects of blindness, 
renal damage and particularly cardiovascular and 
cerebrovascular disease (Table 1).37 
Table 1: Showing the symptoms of Diabetes Mellitus in 
Type I and Type II. 
Symptoms Type I Type II 
Hunger Yes Yes 
Onset Fast Slow 
Thirst Yes Yes 
Tiredness Yes Yes 
Polyuria Yes Yes 
Bed Wetting Yes No 
Mood Changes Yes Yes 
Weight Loss Yes Yes 
Visual Disturbances Yes Yes 
Thrush Infection Yes Yes 
Boils Yes Yes 
Pain No Yes 
Unexplained Symptoms Yes Yes 
Occasional Abdominal Pain Yes No 
Diabetic patients have a normal life style but its late 
complications results in reduced life expectancy and 
major health costs. These include diabetic neuropathy, 
diabetic retinopathy and coronary heart disease.27 
Long-term complications 
Long-term complications of DM occur in both forms of 
condition in humans and have an important role in the 
increased morbidity and mortality suffered by these 
individuals. Macrovascular complications include 
coronary heart disease, atherosclerosis, and peripheral 
vascular disease. Microvascular complications include 
retinopathy, nephropathy and neuropathy.32 Over 50% of 
men and women with diabetes have bladder 
dysfunction.24 Diabetic neuropathy is the most common 
complication of this disease and its manifestations can be 
divided into two broad categories, somatic (peripheral) 
and visceral. Disease of the large and small vessels results 
in myocardial infarction, stroke and gangrene of the lower 
extremities. 
 
Diabetic Neuropathy  
Diabetic neuropathies are complex, heterogeneous 
disorders that encompass a wide range of abnormalities 
affecting both peripheral and autonomic nervous 
systems. Diabetes causes various nerve disorders. 
Diabetes neuropathy is a common complication of insulin- 
dependent diabetes mellitus (IDDM) and noninsulin- 
dependent diabetes mellitus (NIDDM). Diabetic 
neuropathies cause numbness and sometimes pain as 
well as weakness in the hands, arms, feet and legs. 
Neurological problems in diabetes may occur in every 
organ system including the digestive tract, heart and 
genitalia. Diabetic neuropathy affects approximately one-
third people of DM which disrupts the nerve supply to the 
bladder. This may increase involuntary bladder 
contractions and decrease bladder sensation. With severe 
neuropathy, function of the detrusor muscle may be 
affected. Diabetic neuropathies are classified as 
peripheral, autonomic, proximal, and focal. Peripheral 
neuropathy is a generalized sensorimotor polyneuropathy 
of gradual onset that is usually progressive. It is the 
earliest and most widely recognized form of diabetic 
neuropathy which affects the lower limbs. Patients 
initially experience sensory manifestations. Loss of deep 
tendon reflexes and poor sensation can also be present. 
Poor sensation in the feet can lead to foot problems and 
may contribute to the development of diabetic ulcers. 
Involvement of motor fibres can cause muscle weakness 
and atrophy leading to feet deformities, which may also 
contribute to ulcers.38,39Autonomic neuropathy causes 
changes in bladder function, digestion, sexual response 
and can also affect the nerves that serve the heart and 
control blood pressure but symptomatic autonomic 
neuropathy is rare. In autonomic neuropathy, male 
erectile dysfunction is more common. Erectile dysfunction 
in diabetes has many causes including anxiety, 
depression, alcohol excess and drugs. Proximal 
neuropathy causes pain in the thighs, hips which causes 
weakness in the legs. Focal neuropathy results in the 
sudden weakness of one nerve or a group of nerves due 
to which muscle weakness or pain occurs. Due to 
neuropathy, loss of tone, incomplete emptying can occur 
resulting in an atonic, painless and distended bladder.27 
Diabetic Retinopathy 
Diabetic retinopathy and blindness from diabetes became 
a significant problem after the discovery of insulin in 1922 
due to the increase in the life expectancy of diabetics. 
Diabetes causes various changes in the retinal circulation, 
causing two forms of retinopathy: non-proliferative and 
the most severe proliferative retinopathy.31 In United 
Kingdom, 5 % of population become blind in past after 30 
years of diabetes. Diabetes causes increased thickness of 
capillary basement membrane and increased permeability 
of the retinal capillaries.27 Ongoing damage leads to blood 
vessels becoming leaky which results in loss of blood. 
Some blood vessels lead to ischemia and release of 
growth factor that stimulate formation of new blood 
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vessels. These blood vessels lack the supportive 
connective tissue and have high risk of haemorrhage due 
to which sudden loss of vision occurs.36 After 20 years of 
type I diabetes almost all patients have retinopathy while 
50- 80% of patients with type II diabetes will have 
retinopathy. Retinal photocoagulation is an effective 
treatment particularly if it is given in early stage when 
patient is symptom less. Without treatment 50% of 
patients become blind within 5 years. Regular screening 
for retinopathy is essential in all diabetic patients.27 
Diabetic Nephropathy 
Diabetic nephropathy occurs in approximately one third 
of both types of diabetics.40 It can be divided into 5 
stages. Stage I occurs at the onset of the disease and is 
characterised by 30%-40% increase in the glomerular 
filtration rate (GFR) above normal. Other changes are 
increase in kidney size, increased glomerular diameter, 
and tubular size.27 Stage II is characterised by normal 
excretion of albumin regardless of the duration of the 
diabetes. Stage III or incipient diabetic nephropathy is 
characterised by microalbuminuria at rest, which can be 
detected by a sensitive method such as 
radioimmunoassay. Stage IV or overt diabetic 
nephropathy is characterized by clinical proteinuria and 
even higher blood pressure than stage III. The 
development of proteinuria and decreased GFR identify 
end-stage renal disease.41,42 
CONCLUSION 
Diabetic bladder dysfunction is relatively common and 
can have different manifestations from detrusor 
instability to poor bladder sensation and contraction. 
Diabetic neuropathy plus detrusor muscle and urothelial 
dysfunctions all have some role in pathophysiology. 
Although scientist explored a lot of pathogenic 
mechanisms of lower urinary tract dysfunction in 
diabetes. There is still lacking of effective screening and 
treatment strategy regarding diabetes.  
REFERENCES  
1. Chowdhary S, Wilcox D, Ransley P, Posterior Urethral 
Valves: Antenatal Diagnosis and Management, Journal of 
Indian Association of Pediatric Surgeons, 8, 2003, 163-168. 
2. Williams P, Gray’s Anatomy The Anatomical Basis of Clinical 
Practise, 38th edition, New York: Edinburgh Churchill 
Livingstone Publication, 1995, 1837-1838. 
3. Tortora G, Derrickson B, Principles of Anatomy and 
Physiology, 11th international edition, John Wiley and Sons 
Publication, 2006, 1024-1025.  
4. Marieb E, Hoehn K, Human Anatomy and Physiology, 7th 
international edition, Pearson Benjamin Cumming 
Publication, 2007, 1024-1026. 
5. Fitzpatrick J, Krane R, The Bladder, Churchill Livingstone 
Publication, 1995, 1-50. 
6. Drake M, Hedlund P, Andersson K, Brading A, Hussain I, 
Fowler C, Landon D, Morphology, phenotype and 
ultrastructure of fibroblastic cells from normal and 
neuropathic human detrusor: absence of myofibroblast 
characteristics, The Journal of Urology, 169,2003, 1573-
1576. 
7. Dixon J, Gosling J, Ultrastructure of smooth muscle cells in 
the urinary system, Ultrastructure of Smooth Muscle, 
London: Kluwer Academic Publication, 1990, 153-169. 
8. Martini F, Fundamentals of Anatomy and Physiology, 7th 
international edition, Pearson Benjamin Cumming 
Publication, 2006, 984-985.    
9. Smith P, Mackler S, Weiser P, Brooker D, Ahn Y, Harte B, 
MCNulty K, Kleyman T, Expression and localization of 
epithelial sodium channel in mammalian urinary bladder, 
American Journal Renal Physiology, 274, 1998,91-96. 
10. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten 
U, van Kerrebroeck P, Victor A, Wein A, The standardisation 
of terminology of lower urinary tract function: Report from 
the Standardisation Sub-committee of the International 
Continence Society, American Journal of Obstetrics and 
Gynecology, 187(1), 2002, 116-126. 
11. Andersson K, Arner A, Urinary Bladder Contraction and 
Relaxation:Physiology and Pathophysiology, American 
Physiological Society, 84, 2004, 935-986. 
12. Thorneloe K, Meredith A, Knorn A, Aldrich R, Nelson M, 
Urodynamic   Properties and neurotransmitter dependence 
of urinary bladder contractility in the BK channel deletion 
model of overactive bladder, American Journal of 
Physiology- Renal Physiology, 289, 2005, 604-610. 
13. Abrams P, Andersson K, Muscarinic receptor antagonists 
for overactive bladder, British Journal of Urology, 100, 
2007, 987-1006. 
14. McCorry L, Physiology of the Autonomic Nervous System, 
American Journal of Pharmaceutical Education, 71(4), 2007, 
1-11.  
15. Yoshimura N, Groat W, Neural Control of the lower Urinary 
Tract, International Journal of Urology, 4, 1997, 111-125. 
16. Wegener J, Schulla V, Lee T, Koller A, Feil S, Feil R, Kleppisch 
T, Klugbauer N, Moosmang S, Welling A, Hofmann F, An 
essential role of Cav1.2 L-type calcium channel for urinary 
bladder function, The Federation of American Societies for 
Experimental Biology, 136, 2004, 1-18. 
17. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano Ken-Ichi, 
Harada Ken-Ichi,    Miyamoto S, Nakazawa H, WON Kyun-
Jong, Sato K, Calcium   Movements, Distribution, and 
Functions in Smooth Muscle, Pharmacological Reviews, 49 
(2), 1997, 157-230.    
18. Webb R, Smooth Muscle and relaxation, The American 
Physiological Society, 27(4), 2003, 201-206. 
19. Bai Y, Sanderson M, Airway smooth muscle relaxation 
results from a reduction in the frequency of Ca2+ 
oscillations induced by a cAMP-mediated inhibition of the 
IP3 receptor, Respiratory Research, 7(34), 2006, 1-20. 
20. Ikebe M, Brozovich F, Protein Kinase C Increases Force and 
Slows Relaxation in Smooth Muscle: Evidence for 
Regulation of the Myosin Light Chain Phosphatase, 
Biochemical and Biophysical Research Communications, 
225, 1996, 370-376. 
Int. J. Pharm. Sci. Rev. Res., 31(1), March – April 2015; Article No. 02, Pages: 13-19                                            ISSN 0976 – 044X 
 
 
International Journal of Pharmaceutical Sciences Review and Research 
Available online at www.globalresearchonline.net  
© Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited. 
 
19 
21. Banting and Best Diabetes Centre, University of Toronto 
(2007). (Online), last accessed at 06/04/2014 at URL   
http://www.bbdc.org/index.htm. 
22. NHS (2008), (Online), last accessed at 04/08/2013 at URL 
www.nhsdirect.nhs.uk/articles/article.aspx?articleId=128&
sectionId=6, 2004. 
23. Rage S, Hall G, Diabetes Emergency and Hospital 
Management, British Medical Journal Publication, 1999, 1-
18. 
24. Brown J, Wessells H, Chancellor M, Howards S, Stamm W, 
Stapleton A, Steers W, McVary K, Urologic Complications of 
Diabetes, Diabetes Care, 28, 2005, 177-185. 
25. Weeratunga P, Jayasinghe S, Perera Y, Jayasena 
G,Jayasinghe S, Per capita sugar consumption and 
prevalence of diabetes mellitus- global and regional 
associations, BMC Public Health, 14 (186), 2014, 1-6. 
26. KaveeshwarSA, Cornwall J, The current state of diabetes 
mellitus in India, Australas Med J., 7(1), 2014, 45-48. 
27. Kumar P, Clark M, Clinical Medicine, 6th edition, Churchill 
Livingstone Publication, 2006, 1101-1151.  
28. Wild S, Roglic G, Green A, Sicree R, King H, Global 
prevalence of diabetes-estimates for the year 2000 and 
projections for 2030, Diabetes Care, 27(3), 2004, 1047-
1053. 
29. Marshall W, Bangert S, Clinical Biochemistry: metabolic and 
clinical aspects. New York Publication, Edinburgh: Churchill 
Livingstone, 2005, 665-678. 
30. Onkamo, P, Vaananen, S, Karvonen M, Tuomilehto J, 
Worldwide increase in incidence of type I diabetes- the 
analysis of the data on published incidence trends, 
Diabetologia, 42, 2006, 1395-1403. 
31. Davidson, Principles and Practice of Medicine, 20thedition, 
Churchill Livingstone Publication, 2006, 805-847.   
32. Pickup C, Williams G, Textbook of diabetes, Blackwell 
Science Private Ltd, London, 1997, 140-155. 
33. Ratner R, Hirsch I, Neifing J, Garg S, Mecca S, Wilson C, Less 
hypoglycaemia with insulin glargine in intensive insulin 
therapy for type I diabetes, U.S. Study Group of Insulin 
Glargine in Type I Diabetes, Diabetes Care, 23, 2000, 639-
643. 
34. Umpierrez E, Casals C, Gebhar P, Diabetic ketoacidosis in 
obese African-Americans, Diabetes, 44, 2005, 790-795. 
35. Sonksen P, Fox C, Judd S, Diabetes, 5th edition, London: 
Class Publishing, 2005, 1- 61  
36. Axford J, O'Callaghan C, Medicine 2nd edition, Oxford: 
Blackwell Science, 2004, 761-817. 
37. Barach J, Historical facts in Diabetes, Annals of Medical 
History, 36, 1928, 324-326.  
38. Davidson B, "Diabetes mellitus: diagnosis and treatment", 
W.B. Saunders company, Los Angeles, California, 1998, 340-
350. 
39. Lifford K, Curhan G, Hu F, Barbieri R, Grodstein F, Type 2 
Diabetes Mellitus and Risk of Developing Urinary 
Incontinence, Journal of the American Geriatrics Society, 
53, 2005, 1851-1857. 
40. O'Bryan T, Hostetter H, The renal hemodynamic basis of 
diabetic nephropathy, Seminars in Nephrology,17, 1997, 
93-100. 
41. Marshall M, The Diabetes Annual., 11, 1998, 169-194.  
42. Nathan M, Long-term complications of diabetes mellitus, 







Source of Support: Nil, Conflict of Interest: None. 
  
